However, current EpCAM-dependent antibody capture and CK-dependent identification strategies are restricted and biased to the only both CK and EpCAM positive CTCs [8, 14], thus having significant limitations particularly in their ability to capture and identify CTCs shed from several different types of cancer including lung (NSCLC), melanoma, glioma, renal cell and pancreatic cancers, etc. [8,9,14]. Here, EPCAM is linked to familial pancreatic carcinoma.